Core Viewpoint - The market price of 7-ACA is influenced by various factors, including changes in upstream chemical prices, industry supply and demand dynamics, production costs, and downstream market demand [1] Group 1: Company Insights - The company will closely monitor the trends in upstream raw material prices and overall market changes [1] - The company aims to develop a pricing strategy that considers its production and operational conditions, cost control capabilities, and competitive landscape [1] - The company emphasizes the importance of ensuring the rationality and competitiveness of its pricing strategy [1] Group 2: Industry Dynamics - The pricing of 7-ACA is affected by a combination of upstream chemical prices, supply-demand balance, production costs, and market demand [1] - The company acknowledges the need to consider multiple dynamic factors in the industry when setting prices [1]

Core Viewpoint - The company has fully integrated AI technology into its research, production, and commercialization processes, achieving tangible results through collaborations and innovations [2] Group 1: AI Integration and Achievements - The company has developed a biosynthetic gene cluster prediction algorithm architecture in collaboration with Tencent Quantum Laboratory, resulting in a published paper and a joint application for a national invention patent [2] - The DeepSeek model has been localized and deployed in the research phase, enhancing target identification, molecular design, and clinical trial efficiency [2] - AI is utilized in the production phase to optimize processes, predict capacity, and allocate resources effectively [2] Group 2: Commercialization and Future Plans - An AI agent has provided services to nearly 100,000 patients with chronic diseases, demonstrating the practical application of AI in healthcare [2] - The company plans to continue exploring deep applications of AI in the pharmaceutical and medical fields to drive further technological advancements [2]

Core Viewpoint - The company is actively advancing its financial digitalization system in alignment with industry characteristics and overall group development plans [2] Group 1: Financial Digitalization Efforts - The company is steadily promoting the establishment of a financial digitalization system [2] - It is exploring the feasibility of implementing a financial sharing model [2] - The company is continuously introducing various automation and intelligent digital tools to enhance financial processing efficiency and data management capabilities [2] Group 2: Future Plans - The financial digitalization construction will continue to evolve and improve alongside business development [2] - The company will persist in deepening its financial digitalization and intelligent transformation efforts [2] - Digital capabilities will be leveraged to empower business operations and development [2]

Core Viewpoint - Health元 (600380) reported that as of September 30, 2025, the number of shareholders reached 81,433 [1] Summary by Category - **Company Information** - Health元 has 81,433 shareholders as of the end of Q3 2025 [1]

Core Viewpoint - The company is actively monitoring developments and collaboration opportunities in the AI pharmaceutical sector, aiming to integrate AI technology with innovative drug research and development across the entire industry chain [1] Group 1 - The company is exploring multidimensional AI innovative drug research and development collaborations with quality partners in the industry [1] - The company will evaluate and actively promote any strategic collaboration opportunities that align with its development goals [1] - The company commits to timely information disclosure if there are any substantial advancements in related collaborations [1]

Core Viewpoint - The company is focusing on internationalization as a long-term core development strategy, particularly targeting the EU market for product registration and market expansion [1] Group 1: Business Operations - Currently, the company's exports to the EU market primarily consist of raw materials, which represent a relatively small portion of the overall revenue [1] - Sales in the EU market are mainly conducted through a direct sales model with customers, supplemented by sales through distributors to ensure stable business progress [1] Group 2: Strategic Developments - The company has established a sales subsidiary in the Netherlands and is working on preparations for building a sales and registration system aimed at the EU market, in order to facilitate the future export of formulated products [1] - The company aims to continuously improve its global supply chain and sales layout to enhance its competitiveness in international markets [1]

Group 1 - Seasonal influenza impacts approximately 1 billion people globally each year, with 3 to 5 million cases developing into severe illness and 290,000 to 650,000 deaths due to influenza-related respiratory diseases [1] - The domestic influenza treatment drug market is currently dominated by Dongyangguang Pharmaceutical with Oseltamivir, but new players are rapidly emerging since 2025 [1] - Zhengxiang Pharmaceutical is seeking to list on the Hong Kong Stock Exchange, having submitted its application on January 30, with CICC as its sole sponsor [2][4] Group 2 - Zhengxiang Pharmaceutical's antiviral drug, Marcilosavir, has already been approved for market release, distinguishing it from most other 18A companies [3] - The company was founded in 2018 and has undergone multiple rounds of financing, raising a total of 872 million RMB, with a post-investment valuation of 2.48 billion RMB as of January 2026 [4][5] - The company has a drug portfolio that includes six assets, with Marcilosavir being the core product, which is a new generation antiviral targeting influenza [10][12] Group 3 - The global market for influenza treatment and prevention drugs is projected to reach $4.8 billion by 2024, with China contributing $1.7 billion [16] - The Chinese market for antiviral drugs is expected to grow to 13.6 billion RMB by 2035, with PA inhibitors and other antiviral drugs accounting for 13 billion RMB [17] - Marcilosavir faces competition from several established products, including Roche's Baloxavir and others, with pricing set at 222 RMB per box, which is higher than some competitors [20] Group 4 - Zhengxiang Pharmaceutical reported zero revenue for 2024 and 400,000 RMB for the first nine months of 2025, primarily from regulatory support services for Marcilosavir [23] - The company incurred losses of approximately 145 million RMB for both 2024 and the first nine months of 2025, totaling around 290 million RMB in cumulative losses [23] - The company collaborates with a national CSO, Jichuan Pharmaceutical, to enhance market share through its established distribution network [24] Group 5 - The company has a total of 52 R&D personnel, with significant expenditures on drug development, amounting to 100 million RMB and 81.6 million RMB in R&D costs for the respective reporting periods [23] - As of November 2025, the company had cash and cash equivalents of 523 million RMB and term deposits of 141 million RMB [27] - The overall cash flow from operating activities showed a net outflow of 1.06 billion RMB for 2024, indicating financial challenges [28]

Core Viewpoint - The company has entered into guarantee agreements to support its subsidiaries' financing needs, ensuring operational continuity and financial stability [3][5][13]. Group 1: Guarantee Agreements - In January 2026, the company’s subsidiary, Lijuz Pharmaceutical Group, signed guarantee agreements with three banks, with total guarantee amounts of RMB 10,000 million, RMB 30,000 million, and RMB 60,000 million [3]. - The guarantees are for Lijuz Pharmaceutical's wholly-owned or controlled subsidiaries, and there are no related party guarantees involved [3]. - The company has authorized its legal representative to sign relevant documents regarding the guarantees, assuming joint liability [4][5]. Group 2: Financing Support Framework - A framework agreement was established for Lijuz Group to provide continuous financing guarantees for its subsidiary, Lijuz Monoclonal Antibody, from January 1, 2025, to December 31, 2027, with an annual limit of RMB 21,000 million [5]. - The company will provide counter-guarantees based on its equity stake in Lijuz Monoclonal Antibody, ensuring financial backing until the end of Lijuz Group's guarantee obligations [5][15]. Group 3: Financial Health and Risk Management - As of January 31, 2026, the total guarantee balance of the company is RMB 228,478.14 million, which is 15.72% of the latest audited net assets [16]. - There are no overdue guarantees as of the same date, indicating effective risk management and financial health [17].

健康元药业集团 担保进展公告 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股子公 | 228,478.14 | | 司对外担保余额（万元） | | | 对外担保余额占上市公司最近一期经 | 15.72 | | 审计净资产的比例（%） | | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一期经审 | | | 计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近一期 | | | 经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到或超 | | | 过最近一期经审计净资产 30% | | | 本次对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） | 不适用 | 一、担保情况概述 证券代码：600380 证券简称：健康元 公告编号：临 2026-008 健康元药业集团股份有限公司 关于为控股子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

征祥医药收入高度依赖去年7月获批的流感新药玛硒洛沙韦片，但目前该产品尚未贡献主要收入。其面 临的市场竞争激烈——青峰药业、众生药业的流感药物已先一步获批并进入医保，健康元药业的相关产 品也于去年12月获批。作为后来者，征祥医药亟须突出市场重围。在此背景下，赴港上市成为征祥医药 缓解债务压力、为后续发展寻求资金支持的关键步骤。 背负巨债的征祥医药（南京）集团有限公司（以下简称"征祥医药"），正将其未来押注于一款流感新 药，并由此启动港股上市进程。近日，征祥医药向港交所递交招股书，拟港股上市。招股书显示，2024 年及2025年前三季度，征祥医药营收合计不足40万元，同期亏损累计近3亿元，经营活动现金流持续为 负。截至2025年9月末，负债净额攀升至9.56亿元，资产负债率达415.84%。 在定价策略上，玛硒洛沙韦片的定价与罗氏的玛巴洛沙韦一致，均为222元/盒。相比之下，同为PA抑制 剂的青峰药业的玛舒拉沙韦片和健康元药业的玛帕西沙韦定价分别为175元和198元。征祥医药的产品在 性价比方面并不占优势。 不仅如此，根据京东平台流行性感冒用药排行榜数据，玛巴洛沙韦及磷酸奥司他韦依然占据销量的绝对 主导地位。而在 ...